M. Deenen

发表

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review

H. Guchelaar, H. Gelderblom, I. de Hingh, 2020, Frontiers in Pharmacology.

A unifying model to predict variable drug response for personalised medicine

R. Vossen, S. Anvar, P. Neven, 2020, bioRxiv.

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

J. Schellens, J. Beijnen, M. Deenen, 2013, Therapeutic advances in medical oncology.

Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial

J. Burger, R. Mathijssen, I. de Hingh, 2019, BMJ Open.

Reply to T. Magnes et al.

J. Schellens, J. Beijnen, J. Severens, 2016, Journal of Clinical Oncology.

Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency.

M. Deenen, G. Creemers, Jeroen F Schouten, 2021, Clinical colorectal cancer.

The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.

M. Deenen, P. Houthuizen, R. Grouls, 2019, Pharmacogenetics and genomics.

Screening for polymorphisms in the PXR gene in a Dutch population

J. Schellens, J. Beijnen, M. Deenen, 2006, European Journal of Clinical Pharmacology.

Pharmacogenetic analysis of irreversible severe cisplatin‐induced nephropathy: a case report of a 27‐year‐old woman

J. Schellens, M. Deenen, G. Creemers, 2017, British journal of clinical pharmacology.

Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

M. Deenen, D. Meulendijks, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC)

M. Lahaye, J. Burger, I. de Hingh, 2019, BMJ Open.

Pharmacotherapy within a learning healthcare system: rationale for the Dutch Santeon Farmadatabase

K. Movig, M. Deenen, E. M. van de Garde, 2017, European journal of hospital pharmacy. Science and practice.

The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults

M. Nijziel, M. Deenen, R. Grouls, 2019, European Journal of Clinical Pharmacology.

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

J. Schellens, J. Beijnen, D. Pluim, 2015, Bioanalysis.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions.

L. Brunsveld, M. Deenen, M. Broeren, 2022, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

J. Schellens, H. Rosing, J. Beijnen, 2019, CPT: pharmacometrics & systems pharmacology.

Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis

J. Schellens, J. Beijnen, A. de Boer, 2019, International journal of cancer.

Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.

J. Schellens, H. Boot, M. Deenen, 2010, Annals of internal medicine.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Henk-Jan Guchelaar, Jesse J Swen, J. Schellens, 2016, European journal of cancer.

[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].

J. Schellens, J. Beijnen, M. Deenen, 2012, Nederlands tijdschrift voor geneeskunde.

Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?

J. Schellens, J. Beijnen, M. Deenen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

A Proof of Principle Study of the Terminal Sterilization of Prefilled Syringes Using A Water Cascade Process

M. Deenen, R. Grouls, Anne J.A. Drost-Wijnne, 2018, Pharmaceutical Technology in Hospital Pharmacy.

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.

J. Schellens, J. Beijnen, M. Deenen, 2006, Toxicology and applied pharmacology.

Lower Ribavirin Plasma Concentrations in HCV/HIV–Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage

A. Dofferhoff, M. Deenen, A. J. van der Ven, 2015, Therapeutic drug monitoring.

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

J. Schellens, J. Beijnen, A. Huitema, 2016, European journal of cancer.

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity

J. Schellens, H. Rosing, J. Beijnen, 2017, British Journal of Cancer.

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

J. Sanderson, U. Amstutz, I. Tomlinson, 2015, The Lancet. Oncology.

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction

J. Schellens, J. Beijnen, H. Boot, 2015, Cancer Chemotherapy and Pharmacology.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

J. Schellens, J. Beijnen, H. Boot, 2013, International journal of radiation oncology, biology, physics.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.

H. McLeod, S. Houterman, H. Gelderblom, 2022, European journal of cancer.

Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data

R. Vossen, S. Anvar, P. Neven, 2021, Science Translational Medicine.

First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II)

J. Burger, I. de Hingh, M. Los, 2021, BMJ Open.

Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC)

M. Lahaye, J. Burger, I. de Hingh, 2021, Annals of Surgical Oncology.

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

J. Schellens, R. Mathijssen, T. van Gelder, 2019, Therapeutic advances in medical oncology.

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

J. Schellens, J. Beijnen, K. Sikorska, 2016, The Pharmacogenomics Journal.

Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial

J. Burger, M. Deenen, D. Boerma, 2020, Annals of Surgical Oncology.

RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers: PIPAC-oxaliplatin for peritoneal metastases of gastrointestinal cancers.

I. de Hingh, M. Deenen, K. Rovers, 2021, European journal of cancer.

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.

H. Guchelaar, H. Gelderblom, M. Deenen, 2020, European journal of cancer.

The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients

M. Deenen, E. Aarts, I. Janssen, 2018, Obesity Surgery.

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

C. Punt, J. Schellens, J. Beijnen, 2011, Clinical Cancer Research.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

D. Richel, J. Schellens, J. Beijnen, 2011, Investigational New Drugs.

Increased risk of severe fluoropyrimidine‐associated toxicity in patients carrying a G to C substitution in the first 28‐bp tandem repeat of the thymidylate synthase 2R allele

J. Schellens, J. Beijnen, D. Pluim, 2016, International journal of cancer.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases

J. Schellens, H. Rosing, J. Beijnen, 2018, European Journal of Clinical Pharmacology.

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

E. Smit, C. H. van der Leest, M. Deenen, 2023, Targeted Oncology.

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014

F. Schramel, M. Deenen, B. Peters, 2020, PharmacoEconomics - Open.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity

U. Amstutz, J. Schellens, J. Beijnen, 2016, International journal of cancer.

European Obesity Summit (EOS) – Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1 – 4, 2016: Abstracts

Parashu Ram Pal, S. A. Todd, Jimmy D Bell, 2016, Obesity Facts.

SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Response

J. Schellens, M. Deenen, A. Cats, 2011, Clinical Cancer Research.

Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

R. V. van Schaik, J. Swen, M. Nijenhuis, 2022, European Journal of Human Genetics.

UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.

H. Gelderblom, R. Mathijssen, J. Swen, 2023, Pharmacogenomics.

Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

M. Deenen, D. Meulendijks, 2017 .

ASO Author Reflection: Systemic Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy with Oxaliplatin in Patients with Colorectal Peritoneal Metastases

M. Deenen, I. Hingh, K. Rovers, 2020, Annals of Surgical Oncology.

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

C. Punt, J. Schellens, J. Beijnen, 2011, Clinical Cancer Research.

The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients

M. Deenen, B. Deiman, R. Grouls, 2023, Pharmacy.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

J. Schellens, H. Guchelaar, H. Gelderblom, 2016, European journal of cancer.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases

J. Schellens, H. Rosing, J. Beijnen, 2018, European Journal of Clinical Pharmacology.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

J. Schellens, J. Beijnen, H. Boot, 2013, International journal of radiation oncology, biology, physics.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity

U. Amstutz, J. Schellens, J. Beijnen, 2016, International journal of cancer.

An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.

M. Deenen, A. van der Wekken, D. Moes, 2024, Targeted oncology.